Try our beta test site

Ranolazine for the Treatment of Chest Pain in HCM Patients (RHYME)

This study has been completed.
Gilead Sciences
Information provided by (Responsible Party):
Duke University Identifier:
First received: November 2, 2012
Last updated: November 21, 2016
Last verified: November 2016
Results First Received: November 4, 2016  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Condition: Hypertrophic Cardiomyopathy
Intervention: Drug: Ranolazine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Ranolazine Ranolazine, 500 mg for 60 days

Participant Flow:   Overall Study

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Ranolazine Ranolazine, 500 mg for 60 days

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 63.2  (9.0) 
[Units: Participants]
Count of Participants
Female      8  57.1% 
Male      6  42.9% 
Seattle Angina Questionnaire 
[Units: Units on a scale]
Mean (Standard Deviation)
Physical limitation   49.6  (18.7) 
Anginal stability   45.5  (27.0) 
Anginal frequency   65.5  (13.4) 
Treatment satisfaction   85.2  (12.6) 
Quality of life   40.9  (24.6) 
Kansas City Cardiomyopathy Questionnaire (KCCQ) [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
Physical limitation   61.7  (20.6) 
Symptom stability   43.2  (16.2) 
Symptom frequency   56.4  (20.6) 
Symptom burden   55.3  (29.4) 
Total symptom score   55.9  (24.2) 
Self-efficacy   78.4  (21.7) 
Quality of life   39.4  (26.6) 
Social limitation   46.0  (31.5) 
Overall summary   51.2  (22.3) 
Clinical summary   58.8  (20.9) 
[1] The KCCQ is established, validated 15-question quality of life assessment tool that measures physical limitation, symptom status (frequency, severity, and change over time), social interference from heart failure, and knowledge of disease management.

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety of Ranolazine With Regard to QT Interval   [ Time Frame: 60 Days ]

2.  Primary:   Safety of Ranolazine With Regard to Adverse Events   [ Time Frame: 60 Days ]

3.  Primary:   Safety of Ranolazine With Regard to Drug Tolerability   [ Time Frame: 60 days ]

4.  Secondary:   Improvement in Number of Episodes of Angina Per Week   [ Time Frame: Baseline and 60 Days post treatment ]

5.  Secondary:   Seattle Angina Questionnaire (SAQ)   [ Time Frame: 60 Days post treatment ]

6.  Secondary:   Kansas City Cardiomyopathy Questionnaire (KCCQ)   [ Time Frame: 60 days post treatement ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Andrew Wang, MD
Organization: Duke University Health System
phone: 919-681-6197

Responsible Party: Duke University Identifier: NCT01721967     History of Changes
Other Study ID Numbers: Pro00039302
3938381 ( Other Identifier: Duke University )
Study First Received: November 2, 2012
Results First Received: November 4, 2016
Last Updated: November 21, 2016